Cara Therapeutic (CARA) Stock
CARA is no longer traded. Cara Therapeutic was delisted from the Nasdaq in April 2025.
Prices on this page are historical; the last trade was April 16, 2025 at $18.25.
Cara Therapeutic stock price history
CARA final trading statistics
- Final close
- $18.25
- Final trading day
- Apr 16, 2025
- Market cap at delisting
- $8.11M
- Shares outstanding
- 1.52M
- Final 52-week range
- $0.23 – $25.53
- Avg. volume (final 3 mo.)
- 24,987
- All-time high (split-adj.)
- $1050.84 · Apr 2021
- All-time low (split-adj.)
- $8.73 · Jun 2024
- Return since IPO
- -96.0%
- Beta
- 0.41
- Book value / share
- -$3.01
- Price / book
- -6.05
Cara Therapeutic annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $7.14M | -$70.9M | -$2.73 |
| FY2023 | $20.97M | -$118.5M | -$2.18 |
| FY2022 | $41.87M | -$83.4M | -$1.59 |
| FY2021 | $23.03M | -$88.2M | -$1.73 |
| FY2020 | $135.08M | $8.4M | $0.08 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Cara Therapeutic
Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Cara Therapeutic stock FAQ
What happened to Cara Therapeutic stock?
Cara Therapeutic stock was delisted from the Nasdaq. Its final close was $18.25 on April 16, 2025.
Is CARA stock still trading?
No. CARA was delisted from the Nasdaq in April 2025 and no longer trades on a U.S. exchange.
What was the last price of CARA stock?
CARA closed at $18.25 on its final trading day, April 16, 2025, for a market value of about $8.11M.
What were Cara Therapeutic's revenue and earnings in its last full fiscal year?
Cara Therapeutic reported revenue of $7.14M and net income of -$70.9M in fiscal 2024, its last full year as a public company.
When did Cara Therapeutic go public?
Cara Therapeutic stock began trading on January 31, 2014.